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Abstract
Background: Bone conduction devices are widely used and indicated in cases of conductive, mixed or single sided
deafness where conventional hearing aids are not indicated or tolerated. Percutaneous bone-conduction devices
gave satisfactory hearing outcomes but were frequently complicated by soft tissue reactions. Transcutaneous bone
conduction devices were developed in order to address some of the issues related to the skin-penetrating
abutment. The aim of this article is to present a systematic review of the indications, surgical technique and
audiological, clinical and functional outcomes of the BAHA Attract device reported so far.
Methods: A systematic computer-based literature search was performed on the PubMed database as well as
Scopus, Cochrane and Google Scholar. Out of 497 articles, 10 studies and 89 reported cases were finally included in
our review.
Results: The vast majority of implanted patients were satisfied with the aesthetics of the device scoring highly at
the Abbreviated Profile of Hearing Aid Benefit, Glasgow Benefit Inventory and Client Oriented Scale of
Improvement. Overall, hearing outcomes, tested by various means including speech in noise, free field hearing
testing and word discrimination scores showed a significant improvement. Complications included seroma or
haematoma formation, numbness around the area of the flap, swelling and detachment of the sound processor
from the external magnet.
Conclusions: The functional and audiological results presented so far in the literature have been satisfactory and
the complication rate is low compared to the skin penetrating Bone Conduction Devices. Further robust trials will
be needed to study the long-term outcomes and any adverse effects.
Keywords: BAHA Attract, Transcutaneous bone conduction device, Hearing loss
Background
The notion of bone conduction hearing was mentioned
as early as the second century AD by Claudius Galenus
[1]. Its principle is that sound can be transferred to the
inner ear by skull vibrations, bypassing the external and
middle ear. Bone conduction devices (BCD) are commonly
used in cases of single-sided deafness or conductive/mixed
hearing loss where conventional hearing aids are not indi-
cated or tolerated. Conventional BCD [2] were developed
in the early 20th century and included a sound processor
attached to spectacles or headbands [3]. Disadvantages of
these devices included problems with the skin and soft
tissue under the transducer as well as tension headaches
due to a high static pressure of about 2 N [4], sound at-
tenuation due to soft tissue interposition especially in
frequencies above 1 kHz and issues with feedback [4].
Implanted BCD transmit sound vibrations directly to
skull and were developed to overcome some of the is-
sues mentioned above. They are divided into percutan-
eous (skin penetrating) and transcutaneous (non-skin
penetrating) types.
The Bone Anchored Hearing Aid (BAHA®) was the first
available percutaneous BCD. It is a semi-implantable
under the skin BCD coupled to the skull via an abutment
to a titanium fixture. Presently, there are two companies
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that manufacture the percutaneous BCD: the Swedish
Cochlear Bone Anchored Solutions AB, Mölnlycke, that
manufacture the BAHA® and the Danish Oticon, which
manufacture the Ponto. Their sound processors continu-
ally improve offering higher output capability, improved
transduced technology and better fitting procedure. To
date, more than 150,000 hard of hearing individuals use
BAHA [4–6].
Problems associated with these devices include: wound
dehiscence, recurrent soft tissue reactions and infections
around the abutment are commonly reported (range
8–59 %) which can be daunting both for the patient and
the surgeon and can occasionally lead to revision surgery
(range 5-42 %) [2, 7]. Implant loss rate is reported to be
8.3 %; and it is even higher in the paediatric population
and individuals with learning disabilities [8]. Aesthetic ap-
pearance is also a relative drawback and it is therefore
often not widely acceptable people in adolescence or by
people from different cultural backgrounds [9].
The Bonebridge from MED-EL, Innsbruck, Austria is
a direct-drive BCD that is non-skin penetrating. Its
transducer is completely implanted and the external pro-
cessor is attached to the skin by retention magnets in
the implanted unit [10].
The skin-drive or transcutaneous BCD transmit sound
vibrations through the skin and were developed in order
to address some of the issues related to the presence of
the skin-penetrating abutment. Hugh and colleagues de-
veloped and implanted the first transcutaneous BCD
(Xomed Audiant) and the complication rate dropped
significantly [11]. It was soon taken out of the market
due to poor clinical and audiological outcomes [12].
Following on from this concept, the Sophono device
was developed by Siegert under the name Otomag and
has been available since 2006 [13]. It has two magnets
implanted to the skull by five titanium screws. It uses a
larger contact area, designed to reduce skin pressure,
which in turn might lead to flap problems. When the
skin flap thickness is more than 6 mm, thinning is recom-
mended [14]. A retrospective study on 20 patients with
aural atresia implanted with Sophono, found an average
improvement of 28.6 dB HL on Pure Tone Audiometry
(PTA) and 61.6 % in speech recognition threshold (SRT)
scores compared to the unaided condition [15]. Similar
audiometric results were presented in studies by Magliulo
et al. [16] and O’Niel et al. [17]. In O’Niel’s study, skin
problems following fitting were noticed in 36 % of the
patients and included swelling, irritation, infection, or
pain following prolonged use of the device [17].
The BAHA Attract was launched in 2013 and so far
more than 200 patients have been implanted [6].
This device uses a single magnet that is attached to
the skull with a single titanium fixture. The sound pro-
cessor is attached to a corresponding external magnet
with a soft pad that is used to distribute pressure over the
contact area and decrease skin sensitivity. The innovation
in this BCD is that in cases of conversion to Attract, a pre-
viously fitted osseointegrated fixture can be used to re-
place the abutment with an implant magnet. We present
here a systematic review of the literature.
Methods
A systematic computer-based literature search was per-
formed on the PubMed database as well as Scopus,
Cochrane and Google Scholar. We also searched the grey
literature and the manufacturer’s leaflets and publications.
For each search we used the following free-text search
terms: Term A was ‘BAHA’ or ‘transcutaneous’ and Term
B was ‘Attract’ or ‘hearing’.
Inclusion and exclusion criteria
We have included publications that met the following
criteria:
1] Reports on patients that underwent BAHA Attract
implantation
2] Published in the English language
We have excluded publications that were:
1] Book chapters, letters to the editor and editorials
2] Publications that were relevant to other
transcutaneous devices but BAHA Attract
3] Publications from earlier than 2013 (i.e. before the
BAHA Attract was commercially available)
Results
Search results
Our search strategy on PubMed revealed 497 articles.
After the eligibility assessment 487 publications were ex-
cluded. In total, 10 studies were included in the review.
Figure 1 illustrates the paper selection process.
Audiological and otological indications
According to the manufacturer, patients with unilateral
or bilateral conductive hearing loss (CHL), especially those
with an air-bone gap of more than 30 dB would benefit
from an Attract system with good hearing outcomes. In
cases of mixed hearing loss, patients with a greater air-
bone gap (>30 dB) would benefit more from an Attract
system than an air conduction hearing aid. Regarding the
sensorineural element of hearing loss, a BAHA Attract
could compensate for up to 45 dB HL. Finally patients
with singe-sided deafness [and low transcranial attenu-
ation] would be able to hear due to crossing over of vibra-
tions to the healthy cochlea and able to localise sounds
better. In cases of large transcranial attenuation or moder-
ate mixed hearing loss the patients would most likely
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benefit more from other hearing aid solutions [18]. Pa-
tients with the following Ear Nose and Throat (ENT) con-
ditions would benefit from an Attract system: congenital
malformations, ear canal stenosis, discharging ears with or
without mastoid cavity, previous ear surgery and syndromic
hearing loss (such as in Goldenhar or Treacher Collins)
[18]. Of course each case should be assessed in its own
merits.
Figures 2 and 3 summarize the audiological and oto-
logical indications for implantation of BAHA Attract re-
spectively, based on the cases that were found in the
published studies. Table 1 includes the demographics of
the patients included in the study as well as otological
and audiological indications per study.
In particular, out of the 89 patients included in this
study, 17 (19.1 %) were children under the age of 16.
From the available audiological data in the paediatric
population, 5 (55.6 %) had unilateral SNHL and 4
(44.4 %) had CHL (2 had bilateral CHL and 1 contralateral
mixed HL). In the adult population, 27 (45 %) had CHL,
22 (36.7 %) had unilateral SNHL and 11 (18.3 %) had
mixed hearing loss (bilateral). Otological problems seen in
the children included atresia of the external auditory canal
(EAC) (36.4 %), COM (27.3 %), EAC stenosis (9.1 %), large
vestibular aqueduct and Mondini dysplasia (18.2 %), ossic-
ular abnormality (9.1 %) primary ciliary dyskinesia (9.1 %).
In the adults, the majority had COM (53,3 %), followed by
otosclerosis (20 %), single sided deafness (8.9 %), atresia
(8.9 %), post-viral infection (4.4 %), EAC stenosis (2.2 %)
and post-mastoidectomy (2.2 %).
Evaluation of candidates
The air bone gap in the candidate’s conductive or mixed
hearing loss is a good indicator on whether they would
benefit from an Attract system. So, a proper audiological
evaluation including PTA, speech audiometry and sound
field testing, is essential in the patients’ workup. It is also
important for the patients to try the Attract in different
acoustic environments; this can be done by supplying
them with a BAHA on a softband that that they can use
for a few weeks. An unnecessary, costly procedure can
be prevented that way, if the candidates do not perceive
any benefit from the trial.
Surgery
Surgery can be performed under local or general anaes-
thesia. Gawecki et al. (2016) performed 17 out of 20 cases
under local anaesthesia and suggested that it is feasible in
most adults [19]. Different implant centres’ incision site
might differ slightly from that described in the company’s
Term A
BAHA
Transcutaneous
Term B
Attract
Hearing
497 articles identified
Excluded 487 articles
362 published before 2013
10 not in English
2 reviews/letters to the editor
1 participants non -implanted 
112 not relevant to BAHA 
Attract
10 articles met inclusion 
criteria and included in the 
review
Fig. 1 Illustration of the paper selection process
Fig. 2 Summary of the audiological indications for implantation of
BAHA Attract in the literature
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surgery guide [20] but most follow the typical C-shaped
incision described in the surgery guide. The incision sites
as well as mean surgery time and range per centre are in-
cluded in Table 2. The site of the implant is marked pre-
operatively; the superior edge of the processor is 5-7 cm
posterior to the ear canal at the level of the temporal line.
It is essential that the sound processor does not touch the
pinna. A dot of methylene blue dye is injected deep at the
centre of the implant site to aid correct placement of the
fixture once the flap is raised. Before infiltration of local
anaesthesia, skin thickness is measured in several posi-
tions of the planned implant site. If the soft tissue is
thicker than 6 mm, soft tissue reduction is required to
ensure adequate sound transmission [21]. In a study
by Briggs et al. [22], 3 out of 5 patients with flap thick-
ness >6 mm, had insufficient magnetic retention, des-
pite flap thinning. A 1000 to 1200 C-shaped incision is
made 15 mm away from the marked area, down to
periosteum and a full-thickness scalp flap is raised.
Once adequate dissection is adequate so that the mag-
net template can be placed in a satisfactory position, a
cruciate incision is done in the periosteum, which is
raised to expose enough bone for the implant flange.
A bone bed indicator can be used to determine whether
the surrounding bone requires polishing. Drilling follows
at an angle perpendicular to the bone surface, which aims
to minimise the need for bone polishing later in the
procedure. Once the fixture is in situ, the magnet is
screwed into the implant and tightened to 25 Ncm
using the torque wrench provided. The wound is closed
in layers and a head bandage is applied for 1 to 2 days.
A waiting period of 4–6 weeks for osseo-integration to
take place is necessary before loading of the sound pro-
cessor. A BAHA softwear pad is placed in between the
skin and the external magnet and provides load distri-
bution over the entire surface of the contact area [2].
Outline of studies and audiological outcomes
Table 3 depicts the study design as well as outcome mea-
sures and outcomes per study. Baker et al. (2015) [23], in
Table 1 Patients’ demographics, audiological and otological indications for surgery
Study No of
patients
Gender Mean age (years), age
range
Audiological indications Otological indications
Baker 2015 [23] 6 4 M, 2 F 10.7 (5–15) 5 Unilateral SNHL
1 CHL
N/A
Gawecki 2016 [19] 20 7 M, 13 F 49.8 (25–67) 11 Bilateral Mixed HL
1 Bilateral CHL
8 Unilateral SNHL
8 COM
3 Atresia of EAC
8 otosclerosis
1 post-mumps
Deveze 2015 [6] 1 1 M 65 Unilateral SNHL Post Ramsey-Hunt
Iseri 2014 [24], Iseri 2015
[9]
16 6 M, 10 F 28 (5–52) N/A 14 COM
2 Atresia of EAC
Marsella 2015 [25] 3 N/A 25 (8–44) 3 CHL 2 Atresia of EAC
1 post-mastoidectomy
Clamp 2015 [2]
Briggs 2015 [22]
27 12 M,
15 F
47.5 (range N/A) 17 CHL
10 Unilateral SNHL
N/A
Powell 2015 [26] 6 N/A 16 (8–46) 2 Bilateral CHL
3 Unilateral CHL, Contralateral Mixed
HL
1 Unilateral SNHL
1 SSD
2 LVAS and Mondini
1 Atresia of EAC
1 Meatal stenosis
1 primary ciliary
dyskinesia
Carr 2015 [26] 10 5 M, 5 F 45.8 (21–60) 7 CHL
3 Unilateral SNHL
5 COM
1 Otosclerosis
1 Meatal stenosis
3 SSD
CHL: Conductive Hearing Loss, COM: Chronic Otitis Media, EAC: External Auditory Canal, HL: Hearing Loss, N/A: Not available, No: number, M: Male, F: Female,
SNHL: Sensorineural Hearing Loss, SSD: Sudden Sensorineural Deafness
Fig. 3 Summary of the otological indications for implantation of
BAHA Attract in the literature
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their study performed pre-operative audiometry using
inset of supra-aural headphones and compared with
soundfield post-operatively. Masking was applied to the
non-test ear. In average PTA thresholds were improved
by 41 dBHL and speech reception thresholds by 56 dBHL.
However, measuring hearing thresholds by different means
(inset or supra aural headphones vs. soundfield) can affect
accuracy of statistical analysis. Post-implantation audio-
metric data were missing from one child as the magnet
was not strong enough to hold the sound processor.
Gawecki et al. (2016) [19] reported on their series of 20
adult patients who underwent BAHA Attract implantation.
Table 2 Surgery time, incision, complications and their management
Study Mean surgery time
in minutes, (range)
Surgical incision Complications - Management Outcome
Baker 2015 [23] N/A As per manufacturer 1 seroma - Needle aspiration
1 device detaching
1 Resolved
1 Patient not using device
Gawecki 2016 [19] 44 (30–60) As per manufacturer 2 Haematoma – Compression bandage Resolved
Deveze 2015 [6] N/A Anterior based flap None
Iseri 2014 [24], Iseri 2015 [9] 46 (35–65) Anterior based flap 1 Haematoma – Aspiration
1 Erythema – Reduced magnet strength
3 Erythema and pain – Reduced magnet
strength
Resolved
Marsella 2015 [26] N/A As per manufacturer 1 swelling soft tissue - Antibiotics Resolved
Clamp 2015 [2]
Briggs 2015 [22]
45 (range N/A) As per manufacturer 4 Mild erythema
4 Pain – reduced strength of magnet in
1 patient
Resolved
Powell 2015 [26] N/A N/A 1 Device detaching despite stronger
magnet
1 Sound processor detaching from
external magnet plate
N/A
Carr 2015 [27] 57 (40–80) Inferior based flap 8 Numbness of scalp None
N/A Not available
Table 3 Study design, Outcome measures and results
Study Study Design Outcome measures Results (Mean improvement)
Baker 2015 [23] Retrospective case series Soundfield testing: PTA and SRT PTA: 41 dB HL
SRT: 56 dB HL
Gawecki 2016 [19] Prospective cohort study QoL questionnaires: GBI, APHAB, BAHU
Free field speech in noise audiometry
APHAB: 23.5 % improvement
GBI: 29.6 % improvement
BAHU: “Good” or “very good” by 85 % of patients
Speech in noise: 32.9 %
Deveze 2015 [6] Case report N/A N/A
Iseri 2014 [24], Iseri 2015 [9] Multicentre retrospective
cohort study
Free field PTA and SRT
QoL questionnaires: GBI
PTA: 27.3 dB HL
SRT: 24 dB HL
GBI: 40.5
Marsella 2015 [25] Prospective case series Free field PTA and SRT PTA: 25 dB HL
SRT: 63 %
Clamp 2015 [2]
Briggs 2015 [22]
Multicentre prospective
cohort study
Free field PTA and SRT
Speech in noise audiometry
QoL questionnaire: APHAB
PTA: 18.4 dB HL
SRT: 50 dB HL at 50 dB SPL
Speech in noise: 15 dB HL
APHAB: significant improvement p < 0.05
Powell 2015 [26] Cross-sectional cohort study Free field PTA and SRT
QoL questionnaires: Bone Anchored
Hearing Devices questionnaire
PTA: 30.2
SRT: 72.5
Bone Anchored Hearing Devices Questionnaire:
mean score 9.7/10
Carr 2015 [27] Retrospective cohort study Free field speech discrimination
QoL questionnaires: GBI, COSI
Speech discrimination: 56 % at 50 dBA
GBI:82 % and 91 % (for previously aided vs
not-previously aided patients)
COSI: 86 % of patients could hear in background
noise 95 % of the time
APHAB Abbreviated Profile of Hearing Aid Benefit, BAHU BAHA Aesthetic, hygiene and Use, COSI Client Oriented Scale of Improvement, GBI Glasgow Benefit
Inventory, N/A Not available, PTA Pure Tone Audiometry, QoL: Quality of Life, SRT Speech Reception Thresholds
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They divided their patients in two groups, namely Group
A: 11 patients with bilateral mixed or CHL and Group B:
nine patients with unilateral deafness. The postoperative
audiometric evaluation that was performed in 17 (85 %) pa-
tients, included speech in noise only and revealed a mean
gain of 32.9 %. Iseri et al. (2015) [9] presented the results of
a multi-centre study that aimed to compare BAHA Attract
with percutaneous bone conduction implants. The BAHA
Attract group consisted of 16 patients. Some preliminary
results on 12 of them were already published in 2014 [24].
During surgery, bone polishing was required in 5 patients
and soft tissue reduction in 4 patients. Post-operatively, the
hearing thresholds and SRT were significantly improved
(P < 0.05) when the bone conduction implant was on
than without it. A between group comparison revealed
a significant difference in the SRT results in favour of
the percutaneous BCI group. Marsella et al. (2015) [25]
reported on their experience of 3 patients implanted
with BAHA Attract. The mean gain on PTA was 25 dB.
A better gain was seen in the central frequencies and
lower gain in the lower (250Hz) and higher frequencies
(4 kHz). The SRT post-operatively was 100 % for each
patient, with a mean gain of 63 %. Clamp and Briggs
(2015) [2] presented some initial results from 8 patients
implanted in Melbourne, Australia. This was part of a
multicenter study; the other centres were in Santiago,
Chile; Haifa, Israel and Hong Kong, China. A subsequent
study was published later in 2015 [22] that included an-
other 19 patients. Free field hearing testing showed a
mean gain of 18.4 dB HL over the 4 central frequencies.
Mean improvement in SRT in quiet was 50 % at 50 dB
SPL, 46.4 % at 65 dB SPL and 24.2 % at 80 dB SPL. There
was statistically significant improvement in Speech in
noise Ratio of 15 dB (SD: 12.8 dB) compared to unaided
hearing and 3.8 dB (SD: 7 dB) compared to soft band.
For the Australian arm: Mean speech discrimination
(monosyllabic words in quiet) score gain with BAHA
Attract was 40.7 dB. Speech discrimination in noise
was also improved (mean signal to noise difference gain
of 10.6 dB). Pure Tone Audiometry results were not
available and masking was applied to the contralateral
ear at all conditions. Powell et al. (2015) [26] published
their results on a study that compared outcomes be-
tween 6 patients with BAHA Attract and 6 that were
implanted the Sophono Alpha 1. They concluded that
both systems improved audiological outcomes and there
was no statistically significant difference in aided thresh-
olds or speech discrimination scores between the two de-
vices. Mean unaided PTA was 60.8 dB HL and mean
aided PTA 30.6 dB HL. Most gain was noticed at the
lower and mid frequencies. At 55 dB, unaided SRT were
around 18.5 %, but when aided, they improved to around
87 %. Mean speech perception score gain at 55 dB was
70 %. Carr et al. (2015) [27] reported on 10 patients who
were implanted the BAHA Attract device. They per-
formed word discrimination scores (WDS) in 3 of the
patients with CHL using Boothroyd sentences. When
aided, there was an increase in WDS of 50 % at 30dBA
(from 0 % to 50 %), and 56 % at 50 dBA (32 % to 88 %),
which was not statistically significant. Finally, Deveze et
al. (2015) [6] reported on one case where a percutan-
eous bone conduction implant was changed to a BAHA
Attract due to recurrent episodes of skin reactions
around the abutment (Holgers Grade 3) that failed to
improve despite having a longer abutment fitted and
local treatment. The initial procedure involved soft tis-
sue reduction. Upon removal of the abutment an inter-
val of 2 months was kept for the skin to heal before re-
operating. The authors, concerned about the skin qual-
ity and further pressure to skin by the magnet, used a
superficial fascia temporalis flap that was stitched
around and sheltered the magnet. Audiological results
were not presented however the patient reported a de-
crease in the output compared to the previous percutan-
eous device. It is commonly accepted that the hearing
gain with BAHA Attract is lower than the percutaneous
BAHA, therefore they are best used in patients with
normal or mildly affected cochlear function. If the hearing
deteriorates (e.g. due to aging) conversion to a percutan-
eous BAHA device should be considered and is a straight-
forward procedure since there is no need to replace the
fixture [2].
The studies from Baker et al. (2015) [23] and Powel et
al. (2015) [26] studied predominantly paediatric popula-
tion and both observed greater improvement in mean
aided thresholds (41 dB HL and 30.6 dB HL respectively)
compared to other studies with predominantly adult
population, such as the one from Briggs et al. (2015) [22]
who found improvements of 18.4 dB HL. Similarly, SRT
appeared to be better in the paediatric population. This
can be explained by the thinner soft tissue and less attenu-
ation of vibration in children.
Functional outcomes
In the study by Gawecki et al. (2016) [19], both groups
(Group A: bilateral mixed and conductive hearing loss,
Group B: unilateral deafness) reported significant improve-
ment in the Global score of the Abbreviated Profile of
Hearing Aid Benefit (APHAB) (mean gain: total 23.5 %,
Group A 21.4 %, Group B 26.4 %). Seventeen patients
(85 %) reported that the aesthetic effect of the Attract was
good or very good. Regarding the Glasgow Benefit Inven-
tory (GBI), the mean total score for both groups was 29.6
(general subscale 40.3, social support 13.3, physical
health 3.3). Similarly, in the studies by Iseri et al.
(2014,2015) [9, 24], 97 % of patients completed the GBI
and the mean score was 40.5 (General subscale 47.6,
Social support 28.1, Physical health 23.9). Briggs et al.
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(2015) [22] found a significant improvement in the glo-
bal score of the APHAB (p < 0.05]. Powell et al. (2015)
[26] designed a new questionnaire (Bone Anchored
Hearing Devices Questionnaire) taking into consideration
the Entific medical systems questionnaire and the APHAB.
Quality of life was improved in all 6 patients and their
overall satisfaction on a scale from 0 (very dissatisfied) to
10 (very satisfied) was 9.7. In the study by Carr et al. (2015)
[27] the overall satisfaction scores on GBI for those who
were aided before implantation was 91 % and for those
who were not previously aided was 82 %. Regarding the
Client Oriented Scale of Improvement (COSI), 70 % of
patients responded that they could hear in noisy envi-
ronments 75 % to 95 % of the time and all of them
agreed that the sound quality was good or very good.
Finally, no functional results were presented in the
remaining 2 studies [6, 25].
Complications
A pie chart that displays the complication rates is pre-
sented in Fig. 4. Table 2 presents the complications per
centre along with their management. A common prob-
lem reported amongst the studies is linked to the mag-
net strength; pain and erythema around the implant that
resolve by lowering the magnet’s strength while weak at-
tachment of the magnet is usually resolved by increasing
the magnet strength. There is need to find the ideal bal-
ance between the two in each case. Seroma or haematoma
formation was reported in 4 patients (4.4 %), which was
treated conservatively [9, 19, 23]. Eight patients (8.9 %) re-
ported to have numbness around the area of the flap in a
single study [27]. This probably represents a commoner
problem that is under-reported. One patient (1.1 %) was
treated with antibiotics for a mild swelling that they devel-
oped 7 days post-operatively [25]. In another case (1.1 %)
the sound processor would detach from the external mag-
net [26]. No major differences identified in the complica-
tions between the paediatric and adult patients. There
have been no reports of persistent adverse reactions of
skin due to the magnet up to this intermediate phase.
However, it would be important to look out for any long-
term complications of its use.
Discussion
Strengths and Limitations of the studies and directions
for future studies
A common limitation in the studies described is that
they are observational studies (retrospective or prospective
cohort studies) or case reports rather than Randomised
Controlled Trials; therefore, confounding factors might
have influenced reported outcomes. Some of the studies in-
clude a small number of patients so caution is needed in
generalizing the results. Moreover, the outcome measures
(Audiological and Functional) and the timing of testing
varied greatly amongst the studies making a direct com-
parison difficult. Age and gender matching of participants
in studies that compared different hearing solutions [9, 26]
was not always done although this is hard to achieve in
convenience studies. Finally, data on audiological, oto-
logical indications or functional outcomes were missing
from some of the studies [2, 6, 9, 23, 25]. On the other
hand, most studies had a good follow-up rate of their
cohort and were able to present data for most of the
participants. The manufacturers were not involved in
the design, analysis or publication process of most
studies. More specifically all but three studies disclosed
no conflict of interest. Two studies [6, 23] did not de-
clare any conflict of interest. The study by Briggs et al.
(2015) [22] was sponsored by Cochlear Bone Anchored
Solutions, Mölnlycke, Sweden.
In the future, more robust, well-designed studies with
a higher level of evidence are needed. With rising health-
care costs and a demand for improving technology in
an era of rationalization in healthcare, there is an ever-
increasing need for hard evidence of the cost benefit
ratio of new technology.
Conclusions
This is the first systematic literature review on a new
transcutaneous Bone Conduction Hearing Aid device,
the BAHA Attract by the Cochlear Bone Anchored Solu-
tions AB Mölnlycke, Sweden that was granted approval
in 2013. Once the appropriate candidates have been se-
lected through thorough evaluation the results have been
promising. The surgery is relatively simple and quick and
can be done under local anaesthesia or general anaesthe-
sia. The functional and audiological results presented in
the literature are quite satisfactory and the complication
rate is much less compared to the skin penetrating BCD.
A multi-centre randomized controlled trial that would test
different hearing devices is currently missing from the
literature.
Fig. 4 A pie chart that displays the complication rates of BAHA
Attract implantation
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